Revance Therapeutics, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00BCQ64N4
RVNC
Revance Therapeutics, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Revance Therapeutics, Inc.
ISIN
US7613301099
TICKER
RVNC
MIC
XNAS
REUTERS
RVNC.OQ
BLOOMBERG
RVNC US
F&G:
66
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 28.02.2025
Revance Therapeutics
US7613301099
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024. Revance describes itself as a “biotechnology company that develops, manufactures, and commercializes neuromodulators ...
Revance Therapeutics
Fr., 28.02.2025
Revance Therapeutics
US7613301099
The law firm of Kirby McInerney LLP alerts investors of the imminent March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities between February 29, 2024, through December 6, 2024 (“the Class P...
Revance Therapeutics
Mi., 19.02.2025
Revance Therapeutics
US7613301099
Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as l...
Revance Therapeutics
Fr., 07.02.2025
Revance Therapeutics
US7613301099
Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aestheti...
Revance Therapeutics
Di., 21.01.2025
Revance Therapeutics
US7613301099
Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance”), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the “Second Amendment,” together with the Amended and Restated Merger Agreement, dated December 7, 2024, the “A&R Merger Agreemen...
Revance Therapeutics
So., 19.01.2025
Revance Therapeutics
US7613301099
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Revance Therapeutics
Fr., 10.01.2025
Revance Therapeutics
US7613301099
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for a...
Revance Therapeutics
Fr., 10.01.2025
Revance Therapeutics
US7613301099
Glancy Prongay & Murray LLP reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (th...
Revance Therapeutics
Mi., 08.01.2025
Revance Therapeutics
US7613301099
Law Offices of Howard G. Smith reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”).
IF YOU ARE...
Revance Therapeutics
Mi., 08.01.2025
Revance Therapeutics
US7613301099
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
Revance Therapeutics
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
